Human Growth Hormone

During the Age Management evaluation, we check your human growth hormone level. We perform a blood test called IGF-1.

Growth hormone declines quickly with age. However, we don’t give growth hormone as a replacement. Instead, we provide medication that stimulates your body to make more of your own growth hormone. Therefore, it’s a more natural process.

We offer Sermorelin or a combination of other peptides called Growth Hormone Releasing Peptide-2. The combination may include GHRP-2, GHRP-6, Ipamorelin or CJC-1295. We decide if this medication is right for you through your medical history, physical exam, symptoms and IGF-1 level. Then, if it’s a good fit, these peptides stimulate your body to produce more natural growth hormone. As well as IGF-1.

Growth Hormone FAQ

What should I expect from Sermorelin and related Peptides?

Medications to increase growth hormones have many benefits. These may increase muscle growth and lean muscle mass. Also, it helps you lose weight and decrease body fat percentage. Plus, it boosts energy levels, improves workout recovery and sleep. Added bonus, it may leave you with beautiful hair and nails!

How is it given?

Sermorelin and related peptides are given by SQ injection five nights per week. We recommend having it at bedtime and not eating two hours before the injection.

When will I see results?

Most patients feel the reward of better sleep within a few weeks. Also, this increases energy and improves mood. Most people notice a change in weight loss and muscle mass growth within 3-6 months. For best results, patients should commit at least 3-6 months to achieve the full benefits.

What are the most common side effects? 

The most common side effect is a local injection reaction with pain, swelling and redness. However, it only occurs in 16 percent of people. A small percentage find it bothersome enough to quit therapy. Less than one percent of people have headaches, flushing, dysphagia, dizziness, hyperactivity, somnolence or urticaria.

People with cancer, benign intracranial hypertension and proliferative retinopathy are not eligible for this treatment.

 

 

Share This